Advertisement

Topics

BioTime Reports Third Quarter Results and Recent Corporate Accomplishments

16:05 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Over $40M in recent funding Renevia advancing toward anticipated regulatory approval in Europe OpRegen advancing in clinical trials AgeX distribution expected to be completed...

Other Sources for this Article

Investor Contact:
BioTime, Inc.
David Nakasone, 510-871-4188
dnakasone@biotimeinc.com
or
Media Contact:
JQA Partners, Inc.
Jules Abraham, 917-885-7378
jabraham@jqapartners.com

NEXT ARTICLE

More From BioPortfolio on "BioTime Reports Third Quarter Results and Recent Corporate Accomplishments"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...